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Background: There is a need to have regular updates from regions where high burden of tuberculosis (TB) have been 
reported in order to assist the local and global bodies in their objective to curtail the spread of drug resistant TB 
(DRTB). This study presents a situation report of DRTB in Adamawa State which has been identified as one of the 
States with high burden of TB in Nigeria. 
Materials and Methods: Sputum culture in Lowenstein-Jensen Media, drug sensitivity tests and the GeneXpert 
MTB/Rif analysis were used in the identification and drug susceptibility studies of M. tuberculosis isolates obtained 
from forty TB patients who were enrolled from three selected hospitals with DOTS facilities in the State. 
Results: The age of TB patients range from 17 to 70 years (median = 30 years). Twenty (50 %) M. tuberculosis isolates 
were detected by the GeneXpertMTB/Rif analysis while the media culture detected 31 (77.5%). The two methods 
however detected rifampicin resistance in 4 (10%) of the total isolates. All rifampicin resistant isolates were multidrug 
resistant TB (MDRTB) and three of them were from male patients aged 30, 38 and 45. There was only one case of 
resistance to streptomycin, 3 to ethambutol and 6 to isoniazid. Monoresistance were only observed for ethambutol and 
isoniazid and it was found in two isolates for each. 
Conclusion: There is a need to provide interventions to control MDRTB in the state and to make such interventions 
available and closer to the patients. 
 





Drug resistance complicates the management of tuberculosis (TB) and represents one of the most important 
emerging challenges in the control of TB worldwide (Orenstein et al., 2009; WHO, 2016). It has been shown that 
resistant strains of Mycobacterium tuberculosis, the causative organism of TB, develop as a result of inadequate 
treatment and can propagate to other individuals in the same manner as drug-susceptible ones (Elzinga et al., 2004). 
The drugs used in the treatment of TB are classified into two broad types, which are First Line anti-TB Drugs 
and the Second Line anti-TB Drugs (Chan et al., 2004; Orenstein et al., 2009). The established First Line anti-TB drugs 
such as streptomycin, isoniazid, rifampicin and ethambutol as well as the Second line drugs which include 
pyrazinamide, kanamycin, levofloxacin, capreomycin and etionamide and are used in the two phases of a TB drug 
treatment regimen (Tessema et al., 2009; Kabir et al., 2010; WHO, 2016). 
These two phases of a TB treatment regimen consists of the initial intensive phase of two to three months of 
fully supervised daily administration of drugs and the continuation phase of four to six months applied in the Directly 
Observed Treatment Short Course (DOTS) recommended by the National Tuberculosis and Leprosy Control 
Programme (NTBLCP) (Chan et al., 2004; Orenstein et al., 2009; Kabir et al., 2010). The first line drugs are presented 
as fixed-dose combinations to slow down the possibility of the development of resistance (Kabir et al., 2010). 
Further to these two classes of drugs, various medicinal agents and compounds, such as moxiﬂoxacin, 
gatiﬂoxacin, bedaquiline, imipenem, clofazimine, prochlorperazine and metronidazole as well as β-lactam 
combinations with clavulanate and linezolid have emerged as new classes of anti-M. tuberculosis drugs, offering  
improvements over previously existing treatments (Ginsberg, 2008; Dauby et al., 2011; Wayne et al., 2011; Merle et 
al., 2014; Ruan et al., 2016; Shrivastava et al., 2017).  
Different levels of drug resistance in tuberculosis are known. A patient is said to have Drug-Resistant TB 
(DRTB) if there is a laboratory confirmation of resistance to one or more of the first line anti-TB drugs. Further to this, 
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a patient who has resistant bacilli to one of the first line anti-TB drugs is said to have Mono-Resistance TB (MR-TB). 
Poly-Resistance TB (PR-TB) occurs when there is resistance to more than one of the first line drugs other than 
rifampicin and isoniazid. Patients who have resistant bacilli to both rifampicin and isoniazid are said to be Multi-Drug 
Resistant (MDR-TB) (Kabir et al., 2010; Lamikanra, 2010). 
The final category of DRTB patients involve those with MDR-TB plus resistance to any of the 
fluoroquinolones (ofloxacin, moxifloxacin, levofloxacin) and one of the second line injectables (amikacin, kanamycin, 
and capreomycin). These ones are said to be extended spectrum drug resistant (XDR-TB) (Kabir et al., 2010).  
Extensively drug-resistant TB XDR-TB cases with even broader resistance patterns have been reported in more recent 
years from different countries (Glaziou et al, 2013). 
It has been shown that the effective management of drug resistance is based on preventing the emergence of 
resistant strains through adequate basic treatment of patients, the early detection and proper treatment of existing 
patients with MDR-TB to stop transmission, and measures to limit transmission through infection control (Federal 
Ministry of Health, 2015; WHO, 2016). 
Nigeria ranks fourth in the world and first in Africa in terms of the numbers of people with TB disease, with a 
projected 590,000 incident cases of TB in 2013 and over 600,000 new cases in 2014 (Federal Ministry of Health, 2015; 
Uplekar and Raviglione, 2015, WHO, 2016). The prevalence, incidence and death rate of the disease has always been 
ranked very high with values above 200/100,000, 140/100,000 and 20/100,000 population respectively consistently 
over the past decade (Federal Ministry of Health, 2015).  
The implementation of the DOTS strategy began in Nigeria in 2004 and its uptake has increased since then 
leading to increased case notifications from 31,164 in 2002 to 100,401 in 2013 and greater success in TB management 
(Federal Ministry of Health, 2015). It has been reported that the fact that there are DOTS centres available may 
influence a client‘s willingness to seek for TB diagnostic services, because s/he knows that there is a facility for 
treatment should s/he be diagnosed of TB (Federal Ministry of Health, 2015).  
Adamawa State is one of the states in Nigeria with a high burden of TB (John et al., 2015). As at 2013, it has 
the highest burden of all the states in the North Eastern geographical zone of the country with a value of about 
60/100,000 population (Federal Ministry of Health, 2015). However, drug susceptibility testing is not a routine practice 
in the state (Toma, 2014). As of 2013, out of the 87 centres in Nigeria with the GeneXpert facility, Adamawa state has 
only one which was then at the Specialist Hospital, Yola. Sputum smear microscopy still remains the mainstay of TB 
diagnosis in the State. 
As far as we know, there is presently no report of the prevalence of MDR-TB in Adamawa State in the 
literature. Reports indicate that patients are assumed to have drug-sensitive TB and are generally placed on first line 
anti-TB regimen with the exception of few cases with clear evidence of MDR-TB who are referred to the National TB 
and Leprosy Research Centre, Zaria (Toma, 2014).  
Furthermore, for about a decade, Adamawa State has been involved in dense occurrence of civil unrest due 
mainly to the Boko Haram insurgents, resulting in great socio-economic problems which have been recognized as 
important risk factors in the transmission and rapid spread of TB in high burden communities (Elzinga et al., 2004; 
Glaziou et al., 2013).  
There is a need to have regular updates from regions where high burden of TB have been reported in order to 
assist the local and global bodies in their objective to curtail the spread of DRTB. This study was conducted in order to 
present a situation report of the DRTB in Adamawa State. It is expected that the results obtained from the study would 
guide policy formulation, planning interventions and resource utilization in the enhancement of effective TB treatment 
that should have local and global benefits. 
 
Materials and Methods 
Study Area and Centres 
 
The study area is Adamawa State. Adamawa State is located in North Eastern part of Nigeria and lies between 
latitude 80N and 110N, and longitude 11.50E and 13.50E. The state is bounded by Borno State to the North, Gombe 
and Taraba States to the North/West and South/West respectively, and the Cameroons extending throughout its Eastern 
border. Adamawa state has three Senatorial zones (central, north and south) and 21 local government areas (LGAs). 
Yola is the state capital and sit of the government. Adamawa state has a population density of over 95 person/km2 
arising from a population of over 3.7 million (projected from 2006 National Population Census) with a land mass of 
39,742.12 km2. Adamawa State has over 1,300 health facilities which included; 1 Federal Medical Centre and 6 
General and 7 Cottage Hospitals. The remaining were Clinics, Dispensaries, and Health Posts. Over 1,160 facilities 
were public while about 140 were private (~12%); (https://www.informationng.com/tag/adamawa-state). 
Three Centre were chosen based on the availability of DOTS facilities and from three different geographical 
zones of the State: Specialist Hospital, Yola in the centre, General Hospital, Hong in the North and Cottage Hospital, 
Fufore in the East. As a result of civil unrest due to the activities of the Boko-haram insurgents towards the northern 
part of the state, access to the General Hospital, Hong was reduced. Therefore, the Federal Medical Centre (FMC), 
Yola was used in replacement. The three Centre eventually used for the study were: FMC, Yola; Specialist Hospital, 





adjoining states: Borno, Gombe and Taraba. All patients with suspected TB infection, whether or not they elected to 





Ethical clearances were obtained from the Ministry of Health and Federal Medical Centre (FMC), Yola, 
Adamawa State, Nigeria (Ref. No: S/MOH/s.524/VOL.1/94 and FMCY/SUB/S.9). The study protocol was submitted 





Subjects consist of patients in these hospitals who have been presumptively diagnosed as TB patients and who 
gave written informed consents for participation in the study. The diagnoses of TB were based on the WHO criteria for 
the diagnosis of TB in resource-poor setting (WHO, 2016) and were done by the physician in charge. The diagnoses 
were made using Ziehl-Neelsen (ZN) staining of sputum to identify acid-fast bacilli (AFB). Sputum samples were 




Pulmonary TB patients who were currently receiving anti-TB chemotherapy, patients with extra pulmonary 
TB and those who could not expectorate were excluded. 
 
Sample Size Determination 
 
Sample size determination was done using the formula for sample size calculation for prevalence studies given 
by Araoye (2003). 
n = a2bc/d2, where n = sample size, a = Z statistic for a level of confidence, b = prevalence and d = precision or 
confidence interval. 
The level of confidence of 95% is conventional at which the value for ‘a’ is 1.96 and d is 0.05. Based on WHO 
estimation of DRTB for Africa in 2010 which put DRTB at approximately 5.4% (WHO, 2010), the value of 0.054 was 
used for ‘b’. The equation gave a numerical value for ‘n’ of 79. 
During the collection of samples for the study, the civil unrests in the state also resulted in low attendance for 
care in the three hospitals, hence a smaller number of patients were attended to at the hospitals at the time and these 
adversely affected enrolments for the study. Sample collection started in June 2014 and ended in November 2014 when 
40 subjects had been assessed and difficulty in getting more volunteers aggravated. 
 
Collection and Analysis of Sputum Specimen 
 
Sputum was collected into three separate properly labeled, dry, clean, transparent, leak proof and open-
mouthed sputum sample bottles with cover. One of the sputum samples was collected early in the morning by the 
patient himself after being well instructed on the procedure of collection as previously described (WHO, 2016; Audu et 
al., 2017). This specimen was transported through cold-chain for the probe assay using the GeneXpert MTB/Rif 
machine. 
The remaining two samples were collected following the same procedure used for the first sample but these 
were collected on the spot at the clinic. One of the samples was preserved using a 5-ml cetyl pyridinium chloride 
solution (1%) and stored at room temperature while the other, which serves to authenticate the results obtained from the 
first one, was kept without a preservative in a refrigerator. These two specimens were used for the culture, isolation, 
identification and drug susceptibility testing. Sputum samples without preservatives were sent through cold-chain 
medium while those containing preservatives were sent in cold-box at room temperature. 
 
GeneXpert MTB/Rif Analysis 
 
The GeneXpert MTB/Rif machine was used for the identification and typing of pathogen as well as for the 
probing of resistance to Rifampicin. Sputum samples were processed according to the operating procedures for Gene 
Xpert MTB/RIF assay as previously described (Audu et al., 2017). Results were automatically generated indicating if 
M. tuberculosis was detected or not. Where it was detected, the GeneXpert MTB/Rif automatically generated result 







Culture of Samples 
 
Cultures of the two specimens were done in Lowenstein-Jensen (LJ) Media (both solid and liquid). The 
recommendation of the International Union Against Tuberculosis (IUAT) were followed in the procedures 
(Ananthanarayan and Panicker, 2009) and the culturing took between 4 and 6 weeks for each batch of specimen. 
 
 
Drugs Sensitivity Test (DST) 
 
After the isolation and identification of the organism in LJ media, drug sensitivity was performed by the 
proportion method. The LJ media were prepared for each of the four first line Anti-TB drugs with final concentrations 
of 0.2 μg isoniazid, 2 μg ethambutol, 40 μg rifampicin, and 4 μg streptomycin. Bacterial suspensions were inoculated 
into drug-free and drug-containing slopes of LJ media. Susceptibility or resistance was recorded when the proportion of 




 Of the 40 subjects studied, 24 were males. The age ranges from 17 to 70 years with a median of 30 years. 
From the GeneXpert MTB/Rif analysis, 20 (50 %) of the patients had M. tuberculosis, 32.5 % did not show M. 
tuberculosis infection and the remaining 7.5 % were rejected by the GeneXpert MTB/Rif machine. Four of the M. 
tuberculosis showed rifampicin resistance.  
Culture results in LJ media detected M. tuberculosis in 31 (77.5%) of the patients. A total of 23 (57.5%) of the 
patients had isolates which were susceptible to all the first-line drugs while eight (20%) had isolates which showed 
resistance, four (10%) to only one of the drugs (DR-TB) and the remaining four to more than one (MDR – TB). The 
remaining nine did not grow in culture.  
There was only one case (2.5%) of the total samples resistant to streptomycin, 6 (15%) to isoniazid, 4 (10%) to 
rifampicin and 3 (7.5%) to ethambutol. The one case resistant to streptomycin was simultaneously resistant to isoniazid 
and rifampicin. Also, of the three cases resistant to ethambutol one was resistant to the duo of isoniazid and rifampicin. 
The remaining two MDRTB were resistant to both isoniazid and rifampicin only. All the four isolates that were 
resistant to rifampicin were simultaneously resistant to isoniazid. The remaining two isoniazid resistant isolates were 
mono drug resistant. The four mono drug resistant TB are two cases each for isoniazid and ethambutol (Table 1).  
 Three of the four mono drug resistant strains were from male patients of age 24, 29 and 36 while the only 
female was 35 years of age. The 24 and 29 years old patients were resistant to isoniazid while the 36 years old male 
patient and 35 year old female were resistant to ethambutol. 
Of the four MDRTB patients three were males of age 30, 38 and 45 years while the only female was a 70 year 
old woman. The 30 years old male patient was the one showing MDR to three of the first line drugs: isoniazid, 
rifampicin and ethambutol. While the 45 year old man and the 70 year old woman were the ones with resistance to both 
isoniazid and rifampicin, the 38 year old male patient showed MDR to the three of isoniazid, rifampicin and 




The emergence of MDR-TB poses a threat which, if not effectively addressed, may wipe out the achievements 
of previous efforts in controlling TB. The World Health Organization (WHO) recommends that where possible, 
patients with MDR-TB are treated using ambulatory care rather than models of care based principally on 
hospitalization (WHO, 2016). It has been strongly recommended that any patient identified as suspects for DR-TB 
require urgent intervention to prevent further damage to their lungs and the risk of infection to other patients, 
particularly those debilitated by other medical conditions such as HIV and diabetes (Glaziou et al., 2013). According to 
a report on TB surveillance in Nigeria in 2012, TB has 10 – 15 index rate of being infectious, if one comes in contact 
with somebody who is an active TB patient (Kabir et al., 2010). 
In this study, both the GeneXpert MTB/Rif analysis recommended by the WHO and the culture techniques 
were used for the determination of drug resistant TB strains. Both methods were also used for the species typing of the 
TB pathogen in sputum samples. The two methods showed good correlation in the results obtained for rifampicin 
resistance as both detected four of the isolates that demonstrated resistance to this agent. 
By definition, TB cases that showed resistance to rifampicin are taken as MDR – TB (Abanda et al., 2017). 
This definition is supported by the results of this study in which case all the rifampicin resistant cases also showed 
resistance to at least one other first line drug.  
Results indicate that monoresistance were observed for ethambutol (5%) and isoniazid (5%), but not for 
streptomycin and, as already indicated, rifampicin. The high degree of monoresistance shown to the former agents 
corroborates similar reports from studies conducted in other sections of the country such as seen for Otu et al. (2013) in 





effective being mainly bacteriostatic in action. The comparatively higher susceptibility of the M. tuberculosis strains to 
rifampicin and streptomycin has also been linked to their high bactericidal activity (Lamikanra et al., 2010; Otu et al., 
2013).   
 The results of this study have also shown that most of the rifampicin resistant cases are found in the adult 
males. This corresponds to results obtained in similar studies from different regions of the country such as South-
western States (Daniel and Osman, 2011), health institutions in Calabar, South-East (Otu et al., 2013), and Nasarawa 
State in North-central Nigera (Audu et al., 2017) as well as other areas outside of Nigeria (Coovadia et al., 2013). The 
importance of this could be viewed from two perspectives: health and economic.  
 
From the perspective of health, young adults have high risk index of aggravating TB incidence as well as 
prevalence. This is due to the fact that people in this age range are normally socially vibrant both in term of human 
movements as well as sexual activity. From the economic perspective, adult males are supposed to be the most 
productive in any labour market. They are naturally seen as bread-winners. This is particularly so in a State like 
Adamawa where women have their sustenance culturally attached to males. Hence, economic empowerment of the 
citizens will likely be compromised because of the high rate of prevalence of TB in this group. 
Results indicate that strains with codes 2471, 2633, 2875, 2528  are MDR- TB Group while those with code 
2439, 2486, 2653 and 2488 are mono- resistant group. Since it has been shown that patients with mono-resistance TB 
usually benefit from drug substitution, it is suggested that another drug should be substituted for these cases based on 
the clinical experience of the physician and the pharmacotherapist as well as the results obtained from laboratory drug 
sensitivity tests. For example, patients with strains code 2473 and 2653 that were resistant to isoniazid could be 
substituted with pyrazinamide, one of the highly active second line drugs. In this case, ethionamide should not be 
chosen as substitute because this agent is structurally related to isoniazid and their mechanisms of action and activity 
are also similar. In addition to this, it has been shown that cross-resistance exists between these two agents (Petri, 
2006). 
Although resistance to one drug within a class generally means resistance to all drugs within that class, a 
notable exception is shown in rifabutin. Although rifabutin is structurally similar to rifampicin, rifampicin-resistance 
does not always mean rifabutin-resistance. Thus the laboratory should be asked to test for it to be used as possible 
substitute in cases of rifampicin resistance (Petri, 2006). 
Furthermore, isolates with code 2486 and 2488 that demonstrated mono resistance to ethambutol will also 
enjoy substitution with pyrazinamide. However, in each of these cases, certain clinical considerations such as adverse 
drug reaction should be given priority when substitutions are considered (Lamikanra, 2010). This emphasized the need 
for appropriate pharmaceutical care in the management of these cases. 
In an earlier study, it has been suggested that, when sensitivities are known and the isolate is confirmed as 
resistant to both isoniazid and rifampicin (MDR), five drugs should be chosen in the following order (based on known 
sensitivities). The suggestions given are: an aminoglycoside (e.g., amikacin, kanamycin) or polypeptide antibiotic (e.g., 
capreomycin), PZA, EMB, a fluoroquinolones: with preference for the C-8-methoxy-fluoroquinolones such as 
moxifloxacin or gatifloxacin rather than ciprofloxacin the use of which is more likely to result in the development of 
quinolone resistance (Petri, 2006). It has also been shown that it is not recommended to use more than one injectable 
(STM, capreomycin or amikacin), because the toxic effects of these drugs are additive. Other drugs that are suggested 
are rifabutin, cycloserine, a thioamide: prothionamide or ethionamide, PAS, a macrolide: e.g., clarithromycin, linezolid, 
high-dose isoniazid (if low-level resistance), interferon-γ, thioridazine and meropenem and clavulanic acid (Petri, 2006; 
Glaziou et al., 2013). 
Further to this, these groups of patients require special attention and facilities which if not available in the 
present hospitals, the patients should be immediately referred to those centres with such facilities. It should be noted 
that a holistic approach is imperative in handling resistant TB cases. Hence, no stone should be left untouched in 
identifying and treating prospective resistant TB cases as urgently as possible given the magnitude of the menace such 

























Drug Sensitivity Testing Result to the First Line Anti-TB 
Drugs* 
REMARK 
Streptomycin Isoniazid  Rifampicin  Ethambutol  
1 2420 20 F + + S S S S Non Resistant 
2 689 45 M NC + S S S S Non Resistant 
3 2457 20 M + _ NT NT NT NT Not Applicable 
4 693 67 F NC + S S S S Non Resistant 
5 695 18 M NC + S S S S Non Resistant 
6 2445 18 M Error + S S S S Non Resistant 
7 2437 29 M + + S R S S DR-TB 
8 580 17 F NC + S S S S Non Resistant 
9 2463 41 M + + S S S S Non Resistant 
10 2854 38 F Error _ NT NT NT NT Not Applicable 
11 2469 35 M + + S S S S Non Resistant 
12 2471 30 M Resistant + S R R R MDR-TB 
13 2472 30 M _ + S S S S Non Resistant 
14 2480 42 M + + S S S S Non Resistant 
15 471 17 M Error _ NT NT NT NT Not Applicable 
16 2486 36 M _ + S S S R DR-TB 
17 2483 41 M + + S S S S Non Resistant 
18 2488 35 F + + S S S R DR-TB 
19 2529 29 M + + S S S S Non Resistant 
20 2525 22 M + + S S S S Non Resistant 
21 2633 70 F Resistant + S R R S MDR-TB 
22 2653 24 M + + S R S S DR-TB 
23 2652 18 M + + S S S S Non Resistant 
24 2528 38 M Resistant + R R R S MDR-TB 
25 2675 21 F + + S S S S Non Resistant 
26 XXX 44 F + + S S S S Non Resistant 
27 2884 40 F + + S S S S Non Resistant 
28 2836 40 M _ _ NT NT NT NT Not Applicable 
29 2839 40 M + + S S S S Non Resistant 
30 2821 52 M + + S S S S Non Resistant 
31 658 29 M NC + S S S S Non Resistant 
32 2875 45 M Resistant + S R R S MDR-TB 





34 2901 20 F + _ NT NT NT NT Not Applicable 
35 2695 22 F + + S S S S Non Resistant 
36 2924 20 F _ + S S S S Non Resistant 
37 2943 43 M _ _ NT NT NT NT Not Applicable 
38 2922 30 F _ _ NT NT NT NT Not Applicable 
39 2818 30 F + _ NT NT NT NT Not Applicable 
40 580 17 F NC + S S S S Non Resistant 
KEY: M – Male, F – Female, + = Positive, - = Negative, NC = Not certain, NA = Not Applicable, S = Sensitive, R = Resistant, Error = Rejected by the Gene-Expert machine, DRTB = Drug 































In conclusion, these results provide evidence for the circulation of MDRTB strains in Adamawa State. It also 
provides a confirmation for earlier reports that MDRTB are still prevalent in Nigeria. Therefore, this underscores the 
need to provide interventions to control MDR-TB in the state and to make such interventions available and closer to the 
patients. 
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